Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179676 | 1.00 | HTR2C (0.40) | HTR2CHTR2BHTR2APRKCZACVR1B | |
| Hydrochloric Acid SCHEMBL29756772 | 0.99 | HTR2C (0.39) | HTR2CHTR2BHTR2APRKCZACVR1B | |
| Hydrochloric Acid SCHEMBL20165096 | 0.99 | HTR2C (0.39) | HTR2CHTR2BHTR2APRKCZACVR1B | |
| Hydrochloric Acid SCHEMBL20165098 | 0.99 | HTR2C (0.39) | HTR2CHTR2BHTR2APRKCZACVR1B | |
| SCHEMBL20165126 | 0.87 | ESR1 (0.47) | HTR2CHTR2BPRKCZESR1 | |
| SCHEMBL20165130 | 0.87 | ESR1 (0.47) | HTR2CHTR2BPRKCZESR1 | |
| SCHEMBL29756847 | 0.87 | ESR1 (0.47) | HTR2CHTR2BPRKCZESR1 | |
| SCHEMBL30624598 | 0.78 | PRKCZ (0.41) | HTR2CHTR2BPRKCZ | |
| SCHEMBL26187437 | 0.78 | PRKCZ (0.41) | HTR2CHTR2BPRKCZ | |
| SCHEMBL26187427 | 0.78 | PRKCZ (0.41) | HTR2CHTR2BPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | HTR2C 603/4885HTR2B 771/4885HTR2A 420/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | HTR2C 487/4885HTR2B 593/4885HTR2A 290/4885 |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | HTR2C 478/4885HTR2B 653/4885HTR2A 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.